Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension

George N Sfakianakis, J. J. Bourgoignie, D. Jaffe, G. Kyriakides, E. Perez-Stable, R. C. Duncan

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Renal scintigraphy with [(99m)Tc]diethylenetriaminepentaacetic acid (DTPA) and/or sodium-iodine-131-o-iodohippurate (HIP) was performed before and after an oral dose of captopril (50 mg) in 18 patients with renovascular hypertension (RVH) due to renal artery stenosis (RAS) and 18 controls. In every patient with RVH, captopril induced, enhanced or sustained abnormal findings on HIP scintigraphy depending on the degree of RAS. With DTPA scintigraphy, renal function decreased after captopril in ten kidneys with RVH-related RAS and adequate baseline renal function, but this phenomenon was not evident in 11 kidneys with RVH and poor renal function. Captopril did not influence HIP or DTPA studies of kidneys with patent renal arteries (patients after successful renal angioplasty, patients with essential hypertension, contralateral kidneys of patients with unilateral RVH) or ipsilateral kidneys with mild and subcritical (<60%) RAS in patients without hypertension and/or normal renal vein renin activity. When HIP and DTPA scintigraphy were compared in the same patients, HIP demonstrated greater sensitivity and specificity than DTPA, particularly in patients with poor renal function. HIP scintigraphy before and after a single dose of captopril may provide a rapid sensitive and minimally invasive test for screening patients with hypertension.

Original languageEnglish
Pages (from-to)1383-1392
Number of pages10
JournalJournal of Nuclear Medicine
Volume28
Issue number9
StatePublished - Dec 1 1987

Fingerprint

Renovascular Hypertension
Captopril
Radionuclide Imaging
Kidney
Renal Artery Obstruction
Acids
Hypertension
Renal Veins
Renal Artery
Angioplasty
Renin
Iodine
Sodium

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Sfakianakis, G. N., Bourgoignie, J. J., Jaffe, D., Kyriakides, G., Perez-Stable, E., & Duncan, R. C. (1987). Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension. Journal of Nuclear Medicine, 28(9), 1383-1392.

Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension. / Sfakianakis, George N; Bourgoignie, J. J.; Jaffe, D.; Kyriakides, G.; Perez-Stable, E.; Duncan, R. C.

In: Journal of Nuclear Medicine, Vol. 28, No. 9, 01.12.1987, p. 1383-1392.

Research output: Contribution to journalArticle

Sfakianakis, GN, Bourgoignie, JJ, Jaffe, D, Kyriakides, G, Perez-Stable, E & Duncan, RC 1987, 'Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension', Journal of Nuclear Medicine, vol. 28, no. 9, pp. 1383-1392.
Sfakianakis GN, Bourgoignie JJ, Jaffe D, Kyriakides G, Perez-Stable E, Duncan RC. Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension. Journal of Nuclear Medicine. 1987 Dec 1;28(9):1383-1392.
Sfakianakis, George N ; Bourgoignie, J. J. ; Jaffe, D. ; Kyriakides, G. ; Perez-Stable, E. ; Duncan, R. C. / Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension. In: Journal of Nuclear Medicine. 1987 ; Vol. 28, No. 9. pp. 1383-1392.
@article{c009ebed0f1e4960a2f8aa8508dc06df,
title = "Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension",
abstract = "Renal scintigraphy with [(99m)Tc]diethylenetriaminepentaacetic acid (DTPA) and/or sodium-iodine-131-o-iodohippurate (HIP) was performed before and after an oral dose of captopril (50 mg) in 18 patients with renovascular hypertension (RVH) due to renal artery stenosis (RAS) and 18 controls. In every patient with RVH, captopril induced, enhanced or sustained abnormal findings on HIP scintigraphy depending on the degree of RAS. With DTPA scintigraphy, renal function decreased after captopril in ten kidneys with RVH-related RAS and adequate baseline renal function, but this phenomenon was not evident in 11 kidneys with RVH and poor renal function. Captopril did not influence HIP or DTPA studies of kidneys with patent renal arteries (patients after successful renal angioplasty, patients with essential hypertension, contralateral kidneys of patients with unilateral RVH) or ipsilateral kidneys with mild and subcritical (<60{\%}) RAS in patients without hypertension and/or normal renal vein renin activity. When HIP and DTPA scintigraphy were compared in the same patients, HIP demonstrated greater sensitivity and specificity than DTPA, particularly in patients with poor renal function. HIP scintigraphy before and after a single dose of captopril may provide a rapid sensitive and minimally invasive test for screening patients with hypertension.",
author = "Sfakianakis, {George N} and Bourgoignie, {J. J.} and D. Jaffe and G. Kyriakides and E. Perez-Stable and Duncan, {R. C.}",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "28",
pages = "1383--1392",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "9",

}

TY - JOUR

T1 - Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension

AU - Sfakianakis, George N

AU - Bourgoignie, J. J.

AU - Jaffe, D.

AU - Kyriakides, G.

AU - Perez-Stable, E.

AU - Duncan, R. C.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Renal scintigraphy with [(99m)Tc]diethylenetriaminepentaacetic acid (DTPA) and/or sodium-iodine-131-o-iodohippurate (HIP) was performed before and after an oral dose of captopril (50 mg) in 18 patients with renovascular hypertension (RVH) due to renal artery stenosis (RAS) and 18 controls. In every patient with RVH, captopril induced, enhanced or sustained abnormal findings on HIP scintigraphy depending on the degree of RAS. With DTPA scintigraphy, renal function decreased after captopril in ten kidneys with RVH-related RAS and adequate baseline renal function, but this phenomenon was not evident in 11 kidneys with RVH and poor renal function. Captopril did not influence HIP or DTPA studies of kidneys with patent renal arteries (patients after successful renal angioplasty, patients with essential hypertension, contralateral kidneys of patients with unilateral RVH) or ipsilateral kidneys with mild and subcritical (<60%) RAS in patients without hypertension and/or normal renal vein renin activity. When HIP and DTPA scintigraphy were compared in the same patients, HIP demonstrated greater sensitivity and specificity than DTPA, particularly in patients with poor renal function. HIP scintigraphy before and after a single dose of captopril may provide a rapid sensitive and minimally invasive test for screening patients with hypertension.

AB - Renal scintigraphy with [(99m)Tc]diethylenetriaminepentaacetic acid (DTPA) and/or sodium-iodine-131-o-iodohippurate (HIP) was performed before and after an oral dose of captopril (50 mg) in 18 patients with renovascular hypertension (RVH) due to renal artery stenosis (RAS) and 18 controls. In every patient with RVH, captopril induced, enhanced or sustained abnormal findings on HIP scintigraphy depending on the degree of RAS. With DTPA scintigraphy, renal function decreased after captopril in ten kidneys with RVH-related RAS and adequate baseline renal function, but this phenomenon was not evident in 11 kidneys with RVH and poor renal function. Captopril did not influence HIP or DTPA studies of kidneys with patent renal arteries (patients after successful renal angioplasty, patients with essential hypertension, contralateral kidneys of patients with unilateral RVH) or ipsilateral kidneys with mild and subcritical (<60%) RAS in patients without hypertension and/or normal renal vein renin activity. When HIP and DTPA scintigraphy were compared in the same patients, HIP demonstrated greater sensitivity and specificity than DTPA, particularly in patients with poor renal function. HIP scintigraphy before and after a single dose of captopril may provide a rapid sensitive and minimally invasive test for screening patients with hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0023628849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023628849&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 1383

EP - 1392

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 9

ER -